You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameErgotamine
Accession NumberDB00696  (APRD00677)
TypeSmall Molecule
GroupsApproved
DescriptionA vasoconstrictor found in ergot of Central Europe. It is an alpha-1 selective adrenergic agonist and is commonly used in the treatment of migraine disorders. [PubChem]
Structure
Thumb
Synonyms
(5'alpha)-12'-hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione
12'-Hydroxy-2'-methyl-5'alpha-(phenylmethyl)ergotaman-3',6',18-trione
Ergotamin
Ergotamina
Ergotamine
Ergotaminum
Gynergen
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ergomar Slt 2mgtablet2 mgsublingualAventis Pharma Inc1975-12-312003-07-22Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ergomartablet, orally disintegrating2 mg/1sublingualRosedale Therapeutics2012-08-31Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AnervanRecip
AntimigraineTa Fong
EnxakCazi
ErgamGedeon Richter
Ergo-KranitKrewel Meuselbach
GynaemineSriprasit Dispensary
WigrettesNot Available
Brand mixtures
NameLabellerIngredients
CafergotKAISER FOUNDATION HOSPITALS
Cafergot SupNovartis Pharmaceuticals Canada Inc
Cafergot TabNovartis Pharmaceuticals Canada Inc
Ergodryl CapErfa Canada 2012 Inc
ErgotamineWest ward Pharmaceutical Corp
Ergotamine Tartrate and CaffeineKAISER FOUNDATION HOSPITALS
Gravergol CapsulesCan Med Pharma Inc.
Megral TabsGlaxo Wellcome Inc.
MigergotG&W Laboratories, Inc.
Salts
Name/CASStructureProperties
Ergotamine Tartrate
ThumbNot applicableDBSALT000979
Categories
UNIIPR834Q503T
CAS number113-15-5
WeightAverage: 581.6615
Monoisotopic: 581.263819255
Chemical FormulaC33H35N5O5
InChI KeyInChIKey=XCGSFFUVFURLIX-VFGNJEKYSA-N
InChI
InChI=1S/C33H35N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,15,17,21,25-27,34,42H,7,12-14,16,18H2,1-2H3,(H,35,39)/t21-,25-,26+,27+,32-,33+/m1/s1
IUPAC Name
(4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboxamide
SMILES
[H][C@@]12CCCN1C(=O)[[email protected]](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[[email protected]]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as ergotamines, dihydroergotamines, and derivatives. These are organic compounds containing an ergotamine moiety, which is structurally characterized by a benzyl substituent attached to the piperazine ring of the ergopeptine backbone.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassErgoline and derivatives
Sub ClassLysergic acids and derivatives
Direct ParentErgotamines, dihydroergotamines, and derivatives
Alternative Parents
Substituents
  • Ergotamine
  • Hybrid peptide
  • Lysergic acid amide
  • Indoloquinoline
  • Benzoquinoline
  • Quinoline-3-carboxamide
  • Pyrroloquinoline
  • N-acyl-alpha amino acid or derivatives
  • Quinoline
  • Isoindole or derivatives
  • Indole or derivatives
  • Indole
  • Aralkylamine
  • N-alkylpiperazine
  • Tetrahydropyridine
  • Benzenoid
  • Piperazine
  • Oxazolidinone
  • 1,4-diazinane
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Tertiary carboxylic acid amide
  • Pyrrolidine
  • Pyrrole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Orthocarboxylic acid derivative
  • Lactam
  • Carboxamide group
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Alkanolamine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor use as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants, or so called "histaminic cephalalgia".
PharmacodynamicsErgotamine is a vasoconstrictor and alpha adrenoreceptor antagonist. The pharmacological properties of ergotamine are extremely complex; some of its actions are unrelated to each other, and even mutually antagonistic. The drug has partial agonist and/or antagonist activity against tryptaminergic, dopaminergic and alpha adrenergic receptors depending upon their site, and it is a highly active uterine stimulant. It causes constriction of peripheral and cranial blood vessels and produces depression of central vasomotor centers. The pain of a migraine attack is believed to be due to greatly increased amplitude of pulsations in the cranial arteries, especially the meningeal branches of the external carotid artery. Ergotamine reduces extracranial blood flow, causes a decline in the amplitude of pulsation in the cranial arteries, and decreases hyperperfusion of the territory of the basilar artery. It does not reduce cerebral hemispheric blood flow.
Mechanism of actionErgotamine acts on migraine by one of two proposed mechanisms: 1) activation of 5-HT1D receptors located on intracranial blood vessels, including those on arterio-venous anastomoses, leads to vasoconstriction, which correlates with the relief of migraine headache, and 2) activation of 5-HT1D receptors on sensory nerve endings of the trigeminal system results in the inhibition of pro-inflammatory neuropeptide release.
Related Articles
AbsorptionThe bioavailability of sublingually administered ergotamine has not been determined.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic. Ergotamine is metabolized by the liver by largely undefined pathways, and 90% of the metabolites are excreted in the bile.

Route of eliminationNot Available
Half life2 hours
ClearanceNot Available
ToxicitySigns of overexposure include irritation, nausea, vomiting, headache, diarrhea, thirst, coldness of skin, pruritus, weak pulse, numbness, tingling of extremities, and confusion.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9311
Blood Brain Barrier-0.9644
Caco-2 permeable-0.7317
P-glycoprotein substrateSubstrate0.8678
P-glycoprotein inhibitor IInhibitor0.7801
P-glycoprotein inhibitor IIInhibitor0.6032
Renal organic cation transporterNon-inhibitor0.8178
CYP450 2C9 substrateNon-substrate0.8205
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7408
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.8849
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6759
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9604
BiodegradationNot ready biodegradable0.99
Rat acute toxicity2.9840 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8701
hERG inhibition (predictor II)Non-inhibitor0.6708
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • 3m pharmaceuticals inc
  • Rosedale therapeutics
  • Parke davis div warner lambert co
  • Organon usa inc
Packagers
Dosage forms
FormRouteStrength
Capsuleoral
Tablet, orally disintegratingsublingual2 mg/1
Tabletsublingual2 mg
Tablet, film coatedoral
Tabletoral
Capsule
Suppositoryrectal
Prices
Unit descriptionCostUnit
Ergotamine tartrate powder224.35USD powder
Ergomar 2 mg tablet sl8.97USD tablet
Migergot suppository7.39USD suppository
Cafergot tablet1.89USD tablet
Ergotamine-caffeine tablet1.14USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point213.5 dec °CPhysProp
water solubilitySlightNot Available
logP2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.223 mg/mLALOGPS
logP2.95ALOGPS
logP2.6ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)9.7ChemAxon
pKa (Strongest Basic)7.78ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area118.21 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity160.17 m3·mol-1ChemAxon
Polarizability61.69 Å3ChemAxon
Number of Rings8ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (12 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. Tfelt-Hansen P, Saxena PR, Dahlof C, Pascual J, Lainez M, Henry P, Diener H, Schoenen J, Ferrari MD, Goadsby PJ: Ergotamine in the acute treatment of migraine: a review and European consensus. Brain. 2000 Jan;123 ( Pt 1):9-18. [PubMed:10611116 ]
  2. Schardl CL, Panaccione DG, Tudzynski P: Ergot alkaloids--biology and molecular biology. Alkaloids Chem Biol. 2006;63:45-86. [PubMed:17133714 ]
External Links
ATC CodesN02CA52N02CA72N02CA02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (53.1 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe serum concentration of Ergotamine can be increased when it is combined with 1,10-Phenanthroline.
3,4-DichloroisocoumarinThe serum concentration of Ergotamine can be increased when it is combined with 3,4-Dichloroisocoumarin.
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Ergotamine can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypertensive activities of Ergotamine.
AbirateroneThe serum concentration of Ergotamine can be increased when it is combined with Abiraterone.
AcebutololAcebutolol may increase the vasoconstricting activities of Ergotamine.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Ergotamine.
AcepromazineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Aceprometazine.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Ergotamine.
AcetophenazineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Acetophenazine.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Ergotamine.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Ergotamine.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Ergotamine.
AlfuzosinAlfuzosin may decrease the vasoconstricting activities of Ergotamine.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Ergotamine.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Ergotamine.
AlmotriptanErgotamine may increase the vasoconstricting activities of Almotriptan.
AlogliptinThe serum concentration of Ergotamine can be increased when it is combined with Alogliptin.
Alpha-1-proteinase inhibitorThe serum concentration of Ergotamine can be increased when it is combined with Alpha-1-proteinase inhibitor.
AlprenololAlprenolol may increase the vasoconstricting activities of Ergotamine.
AlprenololErgotamine may increase the atrioventricular blocking (AV block) activities of Alprenolol.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Ergotamine.
AmineptineAmineptine may increase the vasopressor activities of Ergotamine.
AmiodaroneThe metabolism of Ergotamine can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Ergotamine is combined with Amisulpride.
AmitriptylineAmitriptyline may increase the vasopressor activities of Ergotamine.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Ergotamine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ergotamine.
AmperozideThe risk or severity of adverse effects can be increased when Ergotamine is combined with Amperozide.
AmprenavirThe serum concentration of Ergotamine can be increased when it is combined with Amprenavir.
Antithrombin III humanThe serum concentration of Ergotamine can be increased when it is combined with Antithrombin III human.
ApixabanThe serum concentration of Ergotamine can be increased when it is combined with Apixaban.
ApomorphineErgotamine may increase the vasoconstricting activities of Apomorphine.
AprepitantThe serum concentration of Ergotamine can be increased when it is combined with Aprepitant.
AprotininThe serum concentration of Ergotamine can be increased when it is combined with Aprotinin.
ArgatrobanThe serum concentration of Ergotamine can be increased when it is combined with Argatroban.
AripiprazoleThe risk or severity of adverse effects can be increased when Ergotamine is combined with Aripiprazole.
ArotinololArotinolol may increase the vasoconstricting activities of Ergotamine.
ArotinololErgotamine may increase the atrioventricular blocking (AV block) activities of Arotinolol.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Ergotamine.
AsenapineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Asenapine.
AsunaprevirThe serum concentration of Ergotamine can be increased when it is combined with Asunaprevir.
AtazanavirThe serum concentration of Ergotamine can be increased when it is combined with Atazanavir.
AtenololAtenolol may increase the vasoconstricting activities of Ergotamine.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Ergotamine.
AtomoxetineThe metabolism of Ergotamine can be decreased when combined with Atomoxetine.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Ergotamine.
AzaperoneThe risk or severity of adverse effects can be increased when Ergotamine is combined with Azaperone.
AzithromycinThe metabolism of Ergotamine can be decreased when combined with Azithromycin.
BatimastatThe serum concentration of Ergotamine can be increased when it is combined with Batimastat.
BefunololBefunolol may increase the vasoconstricting activities of Ergotamine.
BefunololErgotamine may increase the atrioventricular blocking (AV block) activities of Befunolol.
BenazeprilThe serum concentration of Ergotamine can be increased when it is combined with Benazepril.
BenmoxinBenmoxin may increase the hypertensive activities of Ergotamine.
BenzamidineThe serum concentration of Ergotamine can be increased when it is combined with Benzamidine.
Benzylpenicilloyl PolylysineErgotamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Ergotamine.
BetaxololBetaxolol may increase the vasoconstricting activities of Ergotamine.
BetaxololErgotamine may increase the atrioventricular blocking (AV block) activities of Betaxolol.
BevantololBevantolol may increase the vasoconstricting activities of Ergotamine.
BevantololErgotamine may increase the atrioventricular blocking (AV block) activities of Bevantolol.
BexaroteneThe serum concentration of Ergotamine can be decreased when it is combined with Bexarotene.
BifeprunoxThe risk or severity of adverse effects can be increased when Ergotamine is combined with Bifeprunox.
BisoprololBisoprolol may increase the vasoconstricting activities of Ergotamine.
BisoprololErgotamine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.
BivalirudinThe serum concentration of Ergotamine can be increased when it is combined with Bivalirudin.
BoceprevirThe serum concentration of Ergotamine can be increased when it is combined with Boceprevir.
BopindololBopindolol may increase the vasoconstricting activities of Ergotamine.
BopindololErgotamine may increase the atrioventricular blocking (AV block) activities of Bopindolol.
BortezomibThe metabolism of Ergotamine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Ergotamine can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Ergotamine.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ergotamine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Ergotamine is combined with Brexpiprazole.
BromocriptineBromocriptine may increase the hypertensive activities of Ergotamine.
BromocriptineErgotamine may increase the vasoconstricting activities of Bromocriptine.
BufuralolBufuralol may increase the vasoconstricting activities of Ergotamine.
BufuralolErgotamine may increase the atrioventricular blocking (AV block) activities of Bufuralol.
BupranololBupranolol may increase the vasoconstricting activities of Ergotamine.
BupranololErgotamine may increase the atrioventricular blocking (AV block) activities of Bupranolol.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Ergotamine.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Ergotamine.
CabergolineCabergoline may increase the hypertensive activities of Ergotamine.
CabergolineErgotamine may increase the vasoconstricting activities of Cabergoline.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Ergotamine.
CaffeineThe metabolism of Ergotamine can be decreased when combined with Caffeine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Ergotamine.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Ergotamine.
CandoxatrilThe serum concentration of Ergotamine can be increased when it is combined with Candoxatril.
CaptoprilThe serum concentration of Ergotamine can be increased when it is combined with Captopril.
CarbamazepineThe metabolism of Ergotamine can be increased when combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Ergotamine.
Carboprost TromethamineThe risk or severity of adverse effects can be increased when Carboprost Tromethamine is combined with Ergotamine.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Ergotamine.
CariprazineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Cariprazine.
CaroxazoneCaroxazone may increase the hypertensive activities of Ergotamine.
CarteololCarteolol may increase the vasoconstricting activities of Ergotamine.
CarteololErgotamine may increase the atrioventricular blocking (AV block) activities of Carteolol.
CarvedilolErgotamine may increase the atrioventricular blocking (AV block) activities of Carvedilol.
CarvedilolCarvedilol may decrease the vasoconstricting activities of Ergotamine.
CeliprololCeliprolol may increase the vasoconstricting activities of Ergotamine.
CeliprololErgotamine may increase the atrioventricular blocking (AV block) activities of Celiprolol.
CeritinibThe serum concentration of Ergotamine can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Ergotamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Ergotamine is combined with Chlorprothixene.
ChymostatinThe serum concentration of Ergotamine can be increased when it is combined with Chymostatin.
CilastatinThe serum concentration of Ergotamine can be increased when it is combined with Cilastatin.
CilazaprilThe serum concentration of Ergotamine can be increased when it is combined with Cilazapril.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Ergotamine.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Ergotamine.
CirazolineErgotamine may increase the hypertensive activities of Cirazoline.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Ergotamine.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Ergotamine.
CitalopramThe metabolism of Ergotamine can be decreased when combined with Citalopram.
ClarithromycinThe serum concentration of Ergotamine can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Ergotamine can be decreased when combined with Clemastine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Ergotamine.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Ergotamine.
ClomipramineClomipramine may increase the vasopressor activities of Ergotamine.
ClomipramineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Clomipramine.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Ergotamine.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Ergotamine.
ClotrimazoleThe metabolism of Ergotamine can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Clozapine.
CobicistatThe serum concentration of Ergotamine can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Ergotamine.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Ergotamine.
ConivaptanThe serum concentration of Ergotamine can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Ergotamine.
CrizotinibThe serum concentration of Ergotamine can be increased when it is combined with Crizotinib.
CyamemazineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Cyamemazine.
CyclobenzaprineCyclobenzaprine may increase the vasopressor activities of Ergotamine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Cyclobenzaprine.
CyclosporineThe metabolism of Ergotamine can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Ergotamine.
Cyproterone acetateThe serum concentration of Ergotamine can be decreased when it is combined with Cyproterone acetate.
Dabigatran etexilateThe serum concentration of Ergotamine can be increased when it is combined with Dabigatran etexilate.
DabrafenibThe serum concentration of Ergotamine can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Ergotamine.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Ergotamine.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Ergotamine.
DapiprazoleThe risk or severity of adverse effects can be increased when Ergotamine is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Ergotamine.
DarunavirThe serum concentration of Ergotamine can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Ergotamine can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Ergotamine.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Ergotamine.
DeferasiroxThe serum concentration of Ergotamine can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Ergotamine can be decreased when combined with Delavirdine.
DesipramineDesipramine may increase the vasopressor activities of Ergotamine.
DesipramineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Desipramine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Desvenlafaxine.
DesvenlafaxineDesvenlafaxine may decrease the antihypertensive activities of Ergotamine.
DexamethasoneThe serum concentration of Ergotamine can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Ergotamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Ergotamine.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Ergotamine.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Ergotamine.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Ergotamine.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Ergotamine.
DihydroergotamineDihydroergotamine may increase the hypertensive activities of Ergotamine.
DihydroergotamineErgotamine may increase the vasoconstricting activities of Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Ergotamine.
DiltiazemThe metabolism of Ergotamine can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Ergotamine.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Ergotamine.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Ergotamine.
DolasetronDolasetron may increase the serotonergic activities of Ergotamine.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Ergotamine.
DosulepinDosulepin may increase the vasopressor activities of Ergotamine.
DoxazosinDoxazosin may decrease the vasoconstricting activities of Ergotamine.
DoxepinDoxepin may increase the vasopressor activities of Ergotamine.
DoxepinThe risk or severity of adverse effects can be increased when Ergotamine is combined with Doxepin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Ergotamine.
DoxycyclineThe metabolism of Ergotamine can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Ergotamine can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Ergotamine is combined with Droperidol.
DroxidopaErgotamine may increase the hypertensive activities of Droxidopa.
DuloxetineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Duloxetine.
DuloxetineDuloxetine may decrease the antihypertensive activities of Ergotamine.
EcabetThe serum concentration of Ergotamine can be increased when it is combined with Ecabet.
EdoxabanThe serum concentration of Ergotamine can be increased when it is combined with Edoxaban.
EfavirenzThe serum concentration of Ergotamine can be decreased when it is combined with Efavirenz.
ElafinThe serum concentration of Ergotamine can be increased when it is combined with Elafin.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Ergotamine.
EletriptanErgotamine may increase the vasoconstricting activities of Eletriptan.
EnalaprilThe serum concentration of Ergotamine can be increased when it is combined with Enalapril.
EnalaprilatThe serum concentration of Ergotamine can be increased when it is combined with Enalaprilat.
EnalkirenThe serum concentration of Ergotamine can be increased when it is combined with Enalkiren.
EnzalutamideThe serum concentration of Ergotamine can be decreased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Ergotamine.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergotamine is combined with Ergoloid mesylate.
Ergoloid mesylateErgoloid mesylate may increase the vasoconstricting activities of Ergotamine.
ErgonovineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Ergonovine.
ErgonovineErgonovine may increase the hypertensive activities of Ergotamine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Ergotamine.
ErythromycinThe metabolism of Ergotamine can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Ergotamine.
EscitalopramThe risk or severity of adverse effects can be increased when Ergotamine is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Ergotamine can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineEsmirtazapine may increase the vasopressor activities of Ergotamine.
EsmololEsmolol may increase the vasoconstricting activities of Ergotamine.
EsmololErgotamine may increase the atrioventricular blocking (AV block) activities of Esmolol.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Ergotamine.
EstriolThe serum concentration of Estriol can be increased when it is combined with Ergotamine.
EstroneThe serum concentration of Estrone can be increased when it is combined with Ergotamine.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Ergotamine.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Ergotamine.
EtravirineThe serum concentration of Ergotamine can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Ergotamine.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Ergotamine.
FencamfamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Fencamfamine.
FentanylThe serum concentration of Fentanyl can be decreased when it is combined with Ergotamine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ergotamine.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Ergotamine.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Ergotamine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Ergotamine.
FluconazoleThe metabolism of Ergotamine can be decreased when combined with Fluconazole.
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Ergotamine.
FlupentixolThe risk or severity of adverse effects can be increased when Ergotamine is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Fluphenazine.
FluspirileneThe risk or severity of adverse effects can be increased when Ergotamine is combined with Fluspirilene.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Ergotamine.
FluvoxamineThe metabolism of Ergotamine can be decreased when combined with Fluvoxamine.
FluvoxamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Fluvoxamine.
FosamprenavirThe serum concentration of Ergotamine can be increased when it is combined with Fosamprenavir.
FosaprepitantThe serum concentration of Ergotamine can be increased when it is combined with Fosaprepitant.
FosinoprilThe serum concentration of Ergotamine can be increased when it is combined with Fosinopril.
FosphenytoinThe metabolism of Ergotamine can be increased when combined with Fosphenytoin.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Ergotamine.
FrovatriptanErgotamine may increase the vasoconstricting activities of Frovatriptan.
FurazolidoneFurazolidone may increase the hypertensive activities of Ergotamine.
Fusidic AcidThe serum concentration of Ergotamine can be increased when it is combined with Fusidic Acid.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Ergotamine.
GeldanamycinThe serum concentration of Ergotamine can be increased when it is combined with Geldanamycin.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Ergotamine.
GM6001The serum concentration of Ergotamine can be increased when it is combined with GM6001.
GranisetronGranisetron may increase the serotonergic activities of Ergotamine.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Ergotamine.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Ergotamine.
HaloperidolThe risk or severity of adverse effects can be increased when Ergotamine is combined with Haloperidol.
HirulogThe serum concentration of Ergotamine can be increased when it is combined with Hirulog.
HydracarbazineHydracarbazine may increase the hypertensive activities of Ergotamine.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Ergotamine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Ergotamine.
IdelalisibThe serum concentration of Ergotamine can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Ergotamine is combined with Iloperidone.
ImatinibThe metabolism of Ergotamine can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Ergotamine.
ImipramineImipramine may increase the vasopressor activities of Ergotamine.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Ergotamine.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Ergotamine.
IndenololIndenolol may increase the vasoconstricting activities of Ergotamine.
IndenololErgotamine may increase the atrioventricular blocking (AV block) activities of Indenolol.
IndinavirThe serum concentration of Ergotamine can be increased when it is combined with Indinavir.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Ergotamine.
IndoraminIndoramin may decrease the vasoconstricting activities of Ergotamine.
IproclozideIproclozide may increase the hypertensive activities of Ergotamine.
IproniazidIproniazid may increase the hypertensive activities of Ergotamine.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Ergotamine.
IsavuconazoniumThe metabolism of Ergotamine can be decreased when combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Ergotamine is combined with Isocarboxazid.
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Ergotamine.
IsoflurophateThe serum concentration of Ergotamine can be increased when it is combined with Isoflurophate.
IsradipineThe metabolism of Ergotamine can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Ergotamine can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Ergotamine can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Ergotamine.
IxazomibThe serum concentration of Ergotamine can be increased when it is combined with Ixazomib.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Ergotamine.
KetoconazoleThe serum concentration of Ergotamine can be increased when it is combined with Ketoconazole.
LabetalolErgotamine may increase the atrioventricular blocking (AV block) activities of Labetalol.
LabetalolLabetalol may decrease the vasoconstricting activities of Ergotamine.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Ergotamine.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Ergotamine.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Ergotamine.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Ergotamine.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Ergotamine.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Ergotamine.
LepirudinThe serum concentration of Ergotamine can be increased when it is combined with Lepirudin.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Ergotamine.
LevobunololLevobunolol may increase the vasoconstricting activities of Ergotamine.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Ergotamine.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Ergotamine.
LevomilnacipranLevomilnacipran may decrease the antihypertensive activities of Ergotamine.
LidocaineThe metabolism of Ergotamine can be decreased when combined with Lidocaine.
LinagliptinThe serum concentration of Ergotamine can be increased when it is combined with Linagliptin.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Ergotamine.
LisinoprilThe serum concentration of Ergotamine can be increased when it is combined with Lisinopril.
LisurideErgotamine may increase the vasoconstricting activities of Lisuride.
LithiumThe risk or severity of adverse effects can be increased when Ergotamine is combined with Lithium.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Ergotamine.
LopinavirThe serum concentration of Ergotamine can be increased when it is combined with Lopinavir.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Ergotamine.
LosartanThe serum concentration of Losartan can be increased when it is combined with Ergotamine.
LovastatinThe metabolism of Ergotamine can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Loxapine.
Lu AA21004Ergotamine may increase the vasoconstricting activities of Lu AA21004.
LuliconazoleThe serum concentration of Ergotamine can be increased when it is combined with Luliconazole.
LurasidoneThe risk or severity of adverse effects can be increased when Ergotamine is combined with Lurasidone.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Ergotamine.
MaprotilineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Maprotiline.
MebanazineMebanazine may increase the hypertensive activities of Ergotamine.
MelperoneThe risk or severity of adverse effects can be increased when Ergotamine is combined with Melperone.
MephentermineErgotamine may increase the hypertensive activities of Mephentermine.
MesoridazineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Mesoridazine.
MetaraminolErgotamine may increase the hypertensive activities of Metaraminol.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Ergotamine.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Ergotamine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Methotrimeprazine.
MethoxamineErgotamine may increase the hypertensive activities of Methoxamine.
Methylene blueMethylene blue may increase the hypertensive activities of Ergotamine.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Ergotamine.
MetipranololMetipranolol may increase the vasoconstricting activities of Ergotamine.
MetoclopramideThe risk or severity of adverse effects can be increased when Ergotamine is combined with Metoclopramide.
MetoprololMetoprolol may increase the vasoconstricting activities of Ergotamine.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Ergotamine.
MexiletineThe metabolism of Ergotamine can be decreased when combined with Mexiletine.
MianserinThe therapeutic efficacy of Ergotamine can be decreased when used in combination with Mianserin.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Ergotamine.
MidodrineErgotamine may increase the hypertensive activities of Midodrine.
MifepristoneThe serum concentration of Ergotamine can be increased when it is combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Ergotamine is combined with Milnacipran.
MilnacipranMilnacipran may decrease the antihypertensive activities of Ergotamine.
MinaprineMinaprine may increase the hypertensive activities of Ergotamine.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Ergotamine.
MirtazapineMirtazapine may increase the vasopressor activities of Ergotamine.
MirtazapineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Mirtazapine.
MitotaneThe serum concentration of Ergotamine can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Ergotamine.
MoclobemideThe risk or severity of adverse effects can be increased when Ergotamine is combined with Moclobemide.
MoclobemideMoclobemide may increase the hypertensive activities of Ergotamine.
ModafinilThe serum concentration of Ergotamine can be decreased when it is combined with Modafinil.
MoexiprilThe serum concentration of Ergotamine can be increased when it is combined with Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Ergotamine is combined with Molindone.
MorphineThe serum concentration of Morphine can be increased when it is combined with Ergotamine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ergotamine.
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Ergotamine can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.
NadololNadolol may increase the vasoconstricting activities of Ergotamine.
NadololThe serum concentration of Nadolol can be increased when it is combined with Ergotamine.
NafcillinThe serum concentration of Ergotamine can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Ergotamine.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Ergotamine.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Ergotamine.
NaratriptanErgotamine may increase the vasoconstricting activities of Naratriptan.
NCX 4016The serum concentration of Ergotamine can be increased when it is combined with NCX 4016.
NefazodoneThe metabolism of Ergotamine can be decreased when combined with Nefazodone.
NefazodoneThe risk or severity of adverse effects can be increased when Ergotamine is combined with Nefazodone.
NelfinavirThe serum concentration of Ergotamine can be increased when it is combined with Nelfinavir.
NetupitantThe serum concentration of Ergotamine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Ergotamine can be decreased when combined with Nevirapine.
NialamideNialamide may increase the hypertensive activities of Ergotamine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Ergotamine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Ergotamine.
NilotinibThe metabolism of Ergotamine can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Ergotamine.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Ergotamine.
NitroglycerinErgotamine may decrease the vasodilatory activities of Nitroglycerin.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Ergotamine.
NortriptylineNortriptyline may increase the vasopressor activities of Ergotamine.
NortriptylineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Nortriptyline.
OctamoxinOctamoxin may increase the hypertensive activities of Ergotamine.
OlanzapineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Olanzapine.
OlaparibThe metabolism of Ergotamine can be decreased when combined with Olaparib.
OmapatrilatThe serum concentration of Ergotamine can be increased when it is combined with Omapatrilat.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Ergotamine.
OndansetronThe risk or severity of adverse effects can be increased when Ergotamine is combined with Ondansetron.
OndansetronOndansetron may increase the serotonergic activities of Ergotamine.
OsanetantThe risk or severity of adverse effects can be increased when Ergotamine is combined with Osanetant.
OsimertinibThe serum concentration of Ergotamine can be increased when it is combined with Osimertinib.
OtamixabanThe serum concentration of Ergotamine can be increased when it is combined with Otamixaban.
OxprenololOxprenolol may increase the vasoconstricting activities of Ergotamine.
OxprenololErgotamine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Ergotamine.
PalbociclibThe serum concentration of Ergotamine can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Ergotamine is combined with Paliperidone.
PalonosetronPalonosetron may increase the serotonergic activities of Ergotamine.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Ergotamine.
PargylinePargyline may increase the hypertensive activities of Ergotamine.
ParoxetineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Ergotamine.
Peginterferon alfa-2bThe serum concentration of Ergotamine can be increased when it is combined with Peginterferon alfa-2b.
PenbutololPenbutolol may increase the vasoconstricting activities of Ergotamine.
PenbutololErgotamine may increase the atrioventricular blocking (AV block) activities of Penbutolol.
PentobarbitalThe metabolism of Ergotamine can be increased when combined with Pentobarbital.
PergolideErgotamine may increase the vasoconstricting activities of Pergolide.
PerindoprilThe serum concentration of Ergotamine can be increased when it is combined with Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Ergotamine is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ergotamine.
PhenelzineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Phenelzine.
PhenelzinePhenelzine may increase the hypertensive activities of Ergotamine.
PheniprazinePheniprazine may increase the hypertensive activities of Ergotamine.
PhenobarbitalThe metabolism of Ergotamine can be increased when combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Ergotamine.
PhenoxypropazinePhenoxypropazine may increase the hypertensive activities of Ergotamine.
PhenylephrineErgotamine may increase the hypertensive activities of Phenylephrine.
PhenytoinThe metabolism of Ergotamine can be increased when combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Ergotamine.
PhosphoramidonThe serum concentration of Ergotamine can be increased when it is combined with Phosphoramidon.
PimozideThe risk or severity of adverse effects can be increased when Ergotamine is combined with Pimozide.
PindololPindolol may increase the vasoconstricting activities of Ergotamine.
PindololErgotamine may increase the atrioventricular blocking (AV block) activities of Pindolol.
PipamperoneThe risk or severity of adverse effects can be increased when Ergotamine is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Pipotiazine.
PirlindolePirlindole may increase the hypertensive activities of Ergotamine.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Ergotamine.
PivhydrazinePivhydrazine may increase the hypertensive activities of Ergotamine.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Ergotamine.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Ergotamine.
PosaconazoleThe serum concentration of Ergotamine can be increased when it is combined with Posaconazole.
PractololPractolol may increase the vasoconstricting activities of Ergotamine.
PractololErgotamine may increase the atrioventricular blocking (AV block) activities of Practolol.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Ergotamine.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Ergotamine.
PrazosinPrazosin may decrease the vasoconstricting activities of Ergotamine.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Ergotamine.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Ergotamine.
PrimidoneThe metabolism of Ergotamine can be increased when combined with Primidone.
PrinomastatThe serum concentration of Ergotamine can be increased when it is combined with Prinomastat.
ProcarbazineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Procarbazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Prochlorperazine.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Ergotamine.
PromazineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Promethazine.
PropericiazineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Propericiazine.
PropranololPropranolol may increase the vasoconstricting activities of Ergotamine.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Ergotamine.
ProtriptylineProtriptyline may increase the vasopressor activities of Ergotamine.
ProtriptylineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Ergotamine.
PRX-00023Ergotamine may increase the vasoconstricting activities of PRX-00023.
QuetiapineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Quetiapine.
QuinaprilThe serum concentration of Ergotamine can be increased when it is combined with Quinapril.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Ergotamine.
QuinineThe serum concentration of Quinine can be increased when it is combined with Ergotamine.
RamiprilThe serum concentration of Ergotamine can be increased when it is combined with Ramipril.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Ergotamine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Ergotamine.
RanolazineThe metabolism of Ergotamine can be decreased when combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Rasagiline.
RasagilineRasagiline may increase the hypertensive activities of Ergotamine.
RemikirenThe serum concentration of Ergotamine can be increased when it is combined with Remikiren.
RemoxiprideThe risk or severity of adverse effects can be increased when Ergotamine is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Reserpine.
RifabutinThe metabolism of Ergotamine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Ergotamine can be increased when combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Ergotamine.
RifapentineThe metabolism of Ergotamine can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Ergotamine.
RisperidoneThe risk or severity of adverse effects can be increased when Ergotamine is combined with Risperidone.
RitonavirThe serum concentration of Ergotamine can be increased when it is combined with Ritonavir.
RivaroxabanThe serum concentration of Ergotamine can be increased when it is combined with Rivaroxaban.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Ergotamine.
RizatriptanErgotamine may increase the vasoconstricting activities of Rizatriptan.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Ergotamine.
RopiniroleThe metabolism of Ergotamine can be decreased when combined with Ropinirole.
RopiniroleErgotamine may increase the vasoconstricting activities of Ropinirole.
SafrazineSafrazine may increase the hypertensive activities of Ergotamine.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Ergotamine.
SaquinavirThe serum concentration of Ergotamine can be increased when it is combined with Saquinavir.
SaxagliptinThe serum concentration of Ergotamine can be increased when it is combined with Saxagliptin.
SelegilineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Selegiline.
SelegilineSelegiline may increase the hypertensive activities of Ergotamine.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Ergotamine.
SertindoleThe risk or severity of adverse effects can be increased when Ergotamine is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Sertraline.
SildenafilThe metabolism of Ergotamine can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Ergotamine.
SilodosinSilodosin may decrease the vasoconstricting activities of Ergotamine.
SiltuximabThe serum concentration of Ergotamine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Ergotamine can be increased when it is combined with Simeprevir.
SitagliptinThe serum concentration of Ergotamine can be increased when it is combined with Sitagliptin.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Ergotamine.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Ergotamine.
SotalolSotalol may increase the vasoconstricting activities of Ergotamine.
SotalolErgotamine may increase the atrioventricular blocking (AV block) activities of Sotalol.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Ergotamine.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Ergotamine.
SpiraprilThe serum concentration of Ergotamine can be increased when it is combined with Spirapril.
St. John's WortThe serum concentration of Ergotamine can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Ergotamine can be increased when it is combined with Stiripentol.
SulfisoxazoleThe metabolism of Ergotamine can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Ergotamine is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Ergotamine.
SumatriptanErgotamine may increase the vasoconstricting activities of Sumatriptan.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Ergotamine.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Ergotamine.
TamsulosinTamsulosin may decrease the vasoconstricting activities of Ergotamine.
TapentadolThe risk or severity of adverse effects can be increased when Ergotamine is combined with Tapentadol.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Ergotamine.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Ergotamine.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Ergotamine.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Ergotamine is combined with Tedizolid Phosphate.
TelaprevirThe serum concentration of Ergotamine can be increased when it is combined with Telaprevir.
TelithromycinThe metabolism of Ergotamine can be decreased when combined with Telithromycin.
TemocaprilThe serum concentration of Ergotamine can be increased when it is combined with Temocapril.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Ergotamine.
TenofovirThe metabolism of Ergotamine can be decreased when combined with Tenofovir.
TerazosinTerazosin may decrease the vasoconstricting activities of Ergotamine.
TeriflunomideThe serum concentration of Ergotamine can be decreased when it is combined with Teriflunomide.
TheophyllineThe metabolism of Ergotamine can be decreased when combined with Theophylline.
ThioproperazineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Thioproperazine.
ThioridazineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Thioridazine.
ThiorphanThe serum concentration of Ergotamine can be increased when it is combined with Thiorphan.
ThiothixeneThe risk or severity of adverse effects can be increased when Ergotamine is combined with Thiothixene.
TianeptineTianeptine may increase the vasopressor activities of Ergotamine.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Ergotamine.
TiclopidineThe metabolism of Ergotamine can be decreased when combined with Ticlopidine.
TimololTimolol may increase the vasoconstricting activities of Ergotamine.
TimololThe serum concentration of Timolol can be increased when it is combined with Ergotamine.
TipranavirThe serum concentration of Ergotamine can be increased when it is combined with Tipranavir.
TocilizumabThe serum concentration of Ergotamine can be decreased when it is combined with Tocilizumab.
ToloxatoneToloxatone may increase the hypertensive activities of Ergotamine.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Ergotamine.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Ergotamine.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Ergotamine.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Ergotamine.
TrandolaprilThe serum concentration of Ergotamine can be increased when it is combined with Trandolapril.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Ergotamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Tranylcypromine.
TranylcypromineTranylcypromine may increase the hypertensive activities of Ergotamine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Ergotamine.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Ergotamine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Triflupromazine.
TrimazosinTrimazosin may decrease the vasoconstricting activities of Ergotamine.
TrimipramineTrimipramine may increase the vasopressor activities of Ergotamine.
TrimipramineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Trimipramine.
UbenimexThe serum concentration of Ergotamine can be increased when it is combined with Ubenimex.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Ergotamine.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Ergotamine.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Ergotamine.
VemurafenibThe serum concentration of Ergotamine can be increased when it is combined with Vemurafenib.
VenlafaxineThe metabolism of Ergotamine can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Ergotamine.
VerapamilThe metabolism of Ergotamine can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Ergotamine.
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Ergotamine.
VilazodoneErgotamine may increase the vasoconstricting activities of Vilazodone.
VildagliptinThe serum concentration of Ergotamine can be increased when it is combined with Vildagliptin.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Ergotamine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Ergotamine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Ergotamine.
VoriconazoleThe serum concentration of Ergotamine can be increased when it is combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Ergotamine.
VortioxetineErgotamine may increase the vasoconstricting activities of Vortioxetine.
XimelagatranThe serum concentration of Ergotamine can be increased when it is combined with Ximelagatran.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Ergotamine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ergotamine is combined with Ziprasidone.
ZiprasidoneThe metabolism of Ergotamine can be decreased when combined with Ziprasidone.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Ergotamine.
ZolmitriptanErgotamine may increase the vasoconstricting activities of Zolmitriptan.
ZotepineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Ergotamine is combined with Zuclopenthixol.
Food Interactions
  • Caffeine increases absorption.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate c...
Gene Name:
HTR1D
Uniprot ID:
P28221
Molecular Weight:
41906.38 Da
References
  1. Silberstein SD, McCrory DC: Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache. 2003 Feb;43(2):144-66. [PubMed:12558771 ]
  2. Lovenberg TW, Erlander MG, Baron BM, Racke M, Slone AL, Siegel BW, Craft CM, Burns JE, Danielson PE, Sutcliffe JG: Molecular cloning and functional expression of 5-HT1E-like rat and human 5-hydroxytryptamine receptor genes. Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2184-8. [PubMed:8384716 ]
  3. Hoyer D, Lery H, Waeber C, Bruinvels AT, Nozulak J, Palacios JM: "5-HT1R" or 5-HT1D sites? Evidence for 5-HT1D binding sites in rabbit brain. Naunyn Schmiedebergs Arch Pharmacol. 1992 Sep;346(3):249-54. [PubMed:1407010 ]
  4. Sanchez-Lopez A, Centurion D, Vazquez E, Arulmani U, Saxena PR, Villalon CM: Pharmacological profile of the 5-HT-induced inhibition of cardioaccelerator sympathetic outflow in pithed rats: correlation with 5-HT1 and putative 5-ht5A/5B receptors. Br J Pharmacol. 2003 Oct;140(4):725-35. Epub 2003 Sep 22. [PubMed:14504136 ]
  5. Deliganis AV, Peroutka SJ: 5-Hydroxtryptamine1D receptor agonism predicts antimigraine efficacy. Headache. 1991 Apr;31(4):228-31. [PubMed:1646776 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of ...
Gene Name:
HTR1B
Uniprot ID:
P28222
Molecular Weight:
43567.535 Da
References
  1. Villalon CM, De Vries P, Rabelo G, Centurion D, Sanchez-Lopez A, Saxena P: Canine external carotid vasoconstriction to methysergide, ergotamine and dihydroergotamine: role of 5-HT1B/1D receptors and alpha2-adrenoceptors. Br J Pharmacol. 1999 Feb;126(3):585-94. [PubMed:10188968 ]
  2. Willems EW, Trion M, De Vries P, Heiligers JP, Villalon CM, Saxena PR: Pharmacological evidence that alpha1-and alpha2-adrenoceptors mediate vasoconstriction of carotid arteriovenous anastomoses in anaesthetized pigs. Br J Pharmacol. 1999 Jul;127(5):1263-71. [PubMed:10455274 ]
  3. Cohen ML, Schenck K: Contractile responses to sumatriptan and ergotamine in the rabbit saphenous vein: effect of selective 5-HT(1F) receptor agonists and PGF(2alpha). Br J Pharmacol. 2000 Oct;131(3):562-8. [PubMed:11015308 ]
  4. Valdivia LF, Centurion D, Arulmani U, Saxena PR, Villalon CM: 5-HT1B receptors, alpha2A/2C- and, to a lesser extent, alpha1-adrenoceptors mediate the external carotid vasoconstriction to ergotamine in vagosympathectomised dogs. Naunyn Schmiedebergs Arch Pharmacol. 2004 Jul;370(1):46-53. Epub 2004 Jun 29. [PubMed:15224175 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Bom AH, Heiligers JP, Saxena PR, Verdouw PD: Reduction of cephalic arteriovenous shunting by ergotamine is not mediated by 5-HT1-like or 5-HT2 receptors. Br J Pharmacol. 1989 Jun;97(2):383-90. [PubMed:2758221 ]
  2. Panconesi A, Anselmi B, Curradi C, Perfetto F, Piluso A, Franchi G: Comparison between venoconstrictor effects of sumatriptan and ergotamine in migraine patients. Headache. 1994 Apr;34(4):194-7. [PubMed:8014033 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Verhoeff NP, Visser WH, Ferrari MD, Saxena PR, van Royen EA: Dopamine D2-receptor imaging with 123I-iodobenzamide SPECT in migraine patients abusing ergotamine: does ergotamine cross the blood brain barrier? Cephalalgia. 1993 Oct;13(5):325-9. [PubMed:8242725 ]
  2. Larson BT, Samford MD, Camden JM, Piper EL, Kerley MS, Paterson JA, Turner JT: Ergovaline binding and activation of D2 dopamine receptors in GH4ZR7 cells. J Anim Sci. 1995 May;73(5):1396-400. [PubMed:7665369 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
partial agonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Gornemann T, Jahnichen S, Schurad B, Latte KP, Horowski R, Tack J, Flieger M, Pertz HH: Pharmacological properties of a wide array of ergolines at functional alpha(1)-adrenoceptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 2008 Jan;376(5):321-30. Epub 2007 Dec 8. [PubMed:18066532 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
partial agonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Gornemann T, Jahnichen S, Schurad B, Latte KP, Horowski R, Tack J, Flieger M, Pertz HH: Pharmacological properties of a wide array of ergolines at functional alpha(1)-adrenoceptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 2008 Jan;376(5):321-30. Epub 2007 Dec 8. [PubMed:18066532 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
partial agonist
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. Gornemann T, Jahnichen S, Schurad B, Latte KP, Horowski R, Tack J, Flieger M, Pertz HH: Pharmacological properties of a wide array of ergolines at functional alpha(1)-adrenoceptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 2008 Jan;376(5):321-30. Epub 2007 Dec 8. [PubMed:18066532 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
partial agonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Gornemann T, Jahnichen S, Schurad B, Latte KP, Horowski R, Tack J, Flieger M, Pertz HH: Pharmacological properties of a wide array of ergolines at functional alpha(1)-adrenoceptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 2008 Jan;376(5):321-30. Epub 2007 Dec 8. [PubMed:18066532 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonistpartial agonist
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Components:
NameUniProt IDDetails
D(1A) dopamine receptorP21728 Details
D(1B) dopamine receptorP21918 Details
References
  1. Bigal ME, Tepper SJ: Ergotamine and dihydroergotamine: a review. Curr Pain Headache Rep. 2003 Feb;7(1):55-62. [PubMed:12525272 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Bigal ME, Tepper SJ: Ergotamine and dihydroergotamine: a review. Curr Pain Headache Rep. 2003 Feb;7(1):55-62. [PubMed:12525272 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity.
Gene Name:
HTR1F
Uniprot ID:
P30939
Molecular Weight:
41708.505 Da
References
  1. Bigal ME, Tepper SJ: Ergotamine and dihydroergotamine: a review. Curr Pain Headache Rep. 2003 Feb;7(1):55-62. [PubMed:12525272 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Bigal ME, Tepper SJ: Ergotamine and dihydroergotamine: a review. Curr Pain Headache Rep. 2003 Feb;7(1):55-62. [PubMed:12525272 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 2002 May;61(5):964-73. [PubMed:11961113 ]
  2. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther. 2002 Oct;303(1):323-32. [PubMed:12235267 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23